Our results show that GLP-1-SSM treatment markedly alleviated the colitis phenotype by reducing the expression of pro-inflammatory cytokine IL-1, increasing goblet cells and preserving intestinal epithelial architecture in colitis model
D ng, pht ban, ni mn
Levodopa is often formulated in combination with decarboxylase inhibitors (e.g., carbidopa, benserazide) to enhance its central bioavailability
Oakland score showed highest specificity for safe discharge in lower GI bleeding by Doug Brunk In a prospective multicenter Canadian study, a score of 8 or less identified patients who could be discharged from the ED, though it was less sensitive than clinical judgment
At a glance Drug / evolocumab (Repatha), a PCSK9-inhibitor biologic antibody Supplement / glutathione (oral, liposomal, or IV forms) Known interaction / none documented in published literature or FDA label Interaction type / not applicable, no shared metabolic pathway identified Evolocumab clearance / proteolytic catabolism, not CYP450 or GSH-dependent Glutathione CYP effect / negligible at typical oral doses (250 to 1,000 mg/day) LDL-C reduction with evolocumab / up to 59% vs
Vesicles of variable sizes produced by a rapid extrusion procedure